CubaHeal Research Department A lifetime risk for a diabetic ulcer in patients suffering from diabetes type 1 or 2 is approximated to 25%,meaning that every fourth person with diabetes will develop diabetic ulcer (1) . Diabetic foot ulcersrepresent a medically significant disease complication, with a high incidence of morbidity and mortalityin the modern world. Risks...
AllCardiovascularChild DevelopmentCuba’s AchievementsCubaHeal NewsDermatologyEducationEndocrinologyGeriatricGynecologyInternational CollaborationMedical (General)NeurologyOncologyOphthalmologyOrthopedicPsychiatrySubstance Abuse RehabilitationTravel InsuranceUncategorized
For Diabetic Foot Ulcer, Heberprot-P is a drug developed by the Center for Genetic Engineering and Biotechnology (CIGB) in 2007 in Cuba. Diabetes is no longer considered life threatening, nonetheless diabetes and complications due to diabetes, when not under control, remain to be sixth leading cause of death having a higher mortality rate than some...